Program Monitoring
6,919
Number of Clinics
54,224
Number of Settlements
4,839,340
Enrollments
20,243,758
Disbursements
Bauchi
1,109
9,202
686,386
2,911,172
Gombe
518
5,164
312,823
1,317,068
Jigawa
785
7,604
880,919
4,039,456
Kaduna
275
2,092
197,835
737,581
Kano
1,260
11,500
943,418
3,668,988
Katsina
1,296
6,443
1,032,537
4,657,739
Kebbi
540
2,950
215,013
798,256
Niger
328
2,246
27,706
40,354
Sokoto
380
2,975
196,490
743,782
Yobe
156
1,805
32,426
47,004
Zamfara
272
2,243
313,787
1,282,358
Vaccination Rate
95.68%
Penta 1
91.22%
Penta 2
88.27%
Penta 3
85.81%
Measles
Bauchi
95.54%
91.43%
88.62%
85.73%
Gombe
96.32%
92.89%
90.28%
87.47%
Jigawa
95.81%
92.38%
90.25%
87.72%
Kaduna
95.6%
90.61%
87.08%
82.89%
Kano
95.09%
91.0%
88.05%
85.14%
Katsina
96.3%
92.74%
90.49%
88.14%
Kebbi
95.15%
88.59%
84.32%
82.45%
Niger
93.21%
83.43%
77.75%
88.48%
Sokoto
94.26%
84.05%
77.95%
74.47%
Yobe
94.94%
90.09%
86.71%
93.97%
Zamfara
96.34%
88.68%
83.67%
83.37%
Impact Evaluation Key Findings
An independent randomized controlled trial found, among other positive findings, that New Incentives’ All Babies program:
Increased Coverage
The program doubled the percentage of infants who were fully vaccinated, increasing coverage from roughly a quarter to just over half of all infants.
Improved Timeliness
Infants who received measles vaccines were 33 percentage points more likely to receive the vaccine within one month of the recommended age.
Improved Knowledge and Attitudes
Caregivers in areas served by the program had better knowledge and more favorable attitudes toward immunization.
Reduced Stockouts
Government clinics with the program were 18 percentage points less likely to report vaccine stockouts during the last 12 months.
Randomized Controlled Trial
Expected in Dec 2020
Study with two-arm cluster RCT
- Control (83 clinics): No intervention, status quo
- Treatment (84 clinics): New Incentives full program
- This design will measure the causal effect of New Incentives' program on the likelihood of an infant receiving a vaccine.
.svg)
.svg)
.png)